**Supplementary Table 1.** **Changes in OST Standing Blood Pressure During Long-Term Open-Label Treatment With Droxidopa\***

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Month of Open-Label Droxidopa** | **n** | **SBP, mmHg** |  | **DBP, mmHg** |
| **SBP Value** | **Change From Baseline** |  | **DBP Value** | **Change From Baseline** |
| Baseline† | 102 | 87.9 (17.5) |  |  | 57.6 (11.2) |  |
| 1 | 92 | 101.8 (24.3) | 13.7 (21.1) |  | 64.6 (13.6) | 6.9 (12.5) |
| 2 | 87 | 98.1 (24.6) | 9.6 (23.0) |  | 61.2 (15.1) | 3.3 (13.5) |
| 3 | 79 | 103.1 (24.0) | 14.0 (22.5) |  | 64.4 (12.7) | 5.9 (11.7) |
| 6 | 67 | 101.2 (25.7) | 10.4 (25.4) |  | 62.8 (16.0) | 3.5 (15.0) |
| 9 | 64 | 97.5 (20.0) | 6.9 (17.5) |  | 61.6 (12.2) | 2.3 (11.1) |
| 12 | 57 | 101.9 (26.2) | 12.3 (26.6) |  | 63.0 (15.0) | 4.3 (13.7) |

DBP=diastolic blood pressure; OST=orthostatic standing test; SBP=systolic blood pressure.

\*Data expressed as mean (SD), excluding missing values, were collected during the OST in all patients who received ≥1 dose of droxidopa. The OST was conducted 3 hours after droxidopa administration.

†Baseline values were measured before the first dose of study treatment in Study NOH301 or NOH302 unless the last visit in Study NOH301 or NOH 302 occurred >1 month before the start of the current study.

**Supplementary Table 2. OHQ Composite Score and Orthostatic Standing Test Results During the DB 2-Week Withdrawal Period\***

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Droxidopa (n=38)** | **Placebo****(n=37)** | **P Value†** |
| **OHQ composite score** |  |  |  |
|  **Baseline**‡ | **6.38 (1.85)** | **6.27 (1.95)** |  |
|  **Randomization**§ | **3.26 (2.58)** | **2.92 (2.65)** |  |
|  **End of 2-week withdrawal** | **3.82 (2.64)** | **3.83 (2.78)** |  |
|  **Change from randomization** | **0.57 (1.89)** | **0.90 (1.55)** | **0.438** |
| **Standing SBP, mmHg** |  |  |  |
|  **Baseline**‡ | **89.4 (15.2)** | **89.8 (19.8)** |  |
|  **Randomization**§ | **104.1 (25.0)** | **101.9 (24.3)** |  |
|  **End of 2-week withdrawal** | **95.7 (19.8)** | **101.8 (24.2)** |  |
|  **Change from randomization** | **–8.4 (26.6)** | **0.0 (18.5)** | **0.286** |
| **Change in standing SBP,**|| **mmHg** |  |  |  |
|  **Baseline**‡ | **–43.3 (21.6)** | **–41.8 (27.3)** |  |
|  **Randomization**§ | **–38.6 (26.4)** | **–34.6 (29.9)** |  |
|  **End of 2-week withdrawal** | **–42.7 (26.3)** | **–28.3 (24.7)** |  |
|  **Change from randomization** | **–4.0 (21.4)** | **6.3 (20.1)** | **0.007** |

**DB=double blind; OHQ=Orthostatic Hypotension Questionnaire; SBP=systolic blood pressure.**

**\*The patient population included all randomized patients who received ≥1 dose of study drug, with the last observation carried forward. Results are shown as mean (SD).**

**†***P* values are based on a nonparametric analysis of covariance model using Mantel-Haenszel methodology based on rank statistics to compare treatment groups with the randomization value as the covariate.

‡Baseline values were measured before the first dose of study treatment in Study NOH301 or NOH302 unless the last visit in Study NOH301 or NOH 302 occurred >1 month before the start of the current study**.**

§Randomization to placebo or droxidopa followed 3 months of open-label droxidopa at an individualized dose.

||**Change in standing SBP is the difference between SBP measured before standing and 3 minutes after standing from a supine** (30° elevation of head and torso) **position.**

**Supplementary Figure Legends**

**Supplementary Figure 1.** Patient Disposition. DB=double-blind; OL=open label; PP=per protocol. \*Patients included in safety analysis. One patient did not meet inclusion criteria of NOH302 and was removed from the study before exposure to droxidopa.

**Supplementary Figure 2.** OHSA and OHDAS composite scores (A), OHDAS individual item scores (B), clinician-reported CGI-I scores (C), and patient-reported CGI-I scores (D). CGI-I=Clinical Global Impression of nOH improvement; OHDAS=Orthostatic Hypotension Daily Activity Scale; OHSA=Orthostatic Hypotension Symptom Assessment.

**Supplementary Figure 1**

****

**Supplementary Figure 2**

